(3S)-1-ethylpiperidin-3-amine | 1149384-34-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (3S)-1-ethylpiperidin-3-amine
• CAS: 1149384-34-8
• 化学式: C₇H₁₆N₂
• 分子量: 128.217
• InChiKey: WAKUKXKZEXFXJP-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3S)-1-ethylpiperidin-3-amine 、 1-氟-2-硝基苯 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Benzimidazole and imidazole inhibitors of histone deacetylases: Synthesis and biological activity

  摘要：

  A series of N-hydroxy-3-[3-(1-substituted-1H-benzoimidazol-2-yl)-phenyl]-acrylamides (5a-5ab) and N-hydroxy-3-[ 3-( 1,4,5-trisubstituted-1H-imidazol-2-yl)-phenyl]-acrylamides (12a-s) were designed, synthesized, and found to be nanomolar inhibitors of human histone deacetylases. Multiple compounds bearing an N1-piperidine demonstrate EC(50)s of 20-100 nM in human A549, HL60, and PC3 cells, in vitro and in vivo hyperacetylation of histones H3 and H4, and induction of p21(waf). Compound 5x displays efficacy in human tumor xenograft models. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.03.092

文献信息

• Pyrrolidine derivatives
  申请人：——

  公开号：US20020049243A1

  公开（公告）日：2002-04-25

  The present invention relates to pyrrolidine derivatives and dimeric forms and/or pharmaceutically acceptable esters, and/or salts thereof. The compounds are useful as inhibitors of metalloproteases, e.g. zinc proteases, particularly zinc hydrolases, and which are effective in treating disease states are associated with vasoconstriction of increasing occurrences.

  本发明涉及吡咯烷衍生物及其二聚体形式和/或药用可接受的酯和/或盐。这些化合物可用作金属蛋白酶抑制剂，例如锌蛋白酶，特别是锌水解酶，对治疗与血管收缩增加发生相关的疾病状态有效。
• [EN] TROPANE COMPOUNDS<br/>[FR] COMPOSÉS DE TROPANE
  申请人：EXELIXIS INC

  公开号：WO2009055077A1

  公开（公告）日：2009-04-30

  A compound according to Formula I or II: (I) or (II) wherein R1, R1b, R2, L1, and L2 and L2b are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

  根据公式I或II的化合物：（I）或（II），其中R1、R1b、R2、L1和L2以及L2b的定义如规范中所述，以及其药物组合物和使用方法。
• INHIBITION OF OLIG2 ACTIVITY
  申请人：Curtana Pharmaceuticals, Inc.

  公开号：US20160237069A1

  公开（公告）日：2016-08-18

  Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.

  本文描述了含有这些化合物的化合物和药物组合物，这些化合物抑制Olig2的活性。本文还描述了使用这种Olig2抑制剂的方法，单独或与其他化合物结合，用于治疗癌症和其他疾病。特别是Olig2抑制剂可以用于治疗胶质母细胞瘤。
• Inhibitors of JNK
  申请人：Arzeno Humberto Bartolome

  公开号：US20110301171A1

  公开（公告）日：2011-12-08

  Compounds of formula I or pharmaceutically acceptable salts thereof, wherein R 5 is a group of formula (a) or (b): and wherein m, n, p, q, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity.

  公式I的化合物或其药用盐，其中R5是公式(a)或(b)的一个基团：其中m、n、p、q、X、Y、R1、R2、R3、R4、R5、R6、R7、R8和R9如本文所定义。本文披露的化合物和组合物可用于调节JNK的活性并治疗与JNK活性相关的疾病。
• Tropane compounds
  申请人：Rice Kenneth D.

  公开号：US20090163471A1

  公开（公告）日：2009-06-25

  A compound according to Formula I or II: wherein R 1 , R 1b , R 2 , L 1 , and L 2 and L 2b are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

  一种符合公式I或II的化合物：其中R1，R1b，R2，L1和L2以及L2b的定义如规范所述，以及其制药组成物和使用方法。